Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 6/20 | 0.46 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.45 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.45 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.45 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.44 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3742473 | 0.91 | KMO (0.51) | TSHRSMN1; SMN2MEN1NPC1ALDH1A1 | |
| SCHEMBL14175879 | 0.91 | TDP1 (0.53) | SMN1; SMN2MEN1KMT2ATDP1S1PR1 | |
| SCHEMBL13078653 | 0.85 | NPC1 (0.55) | TSHRSMN1; SMN2MEN1NPC1ALDH1A1 | |
| SCHEMBL3734547 | 0.84 | NPC1 (0.54) | TSHRSMN1; SMN2MEN1NPC1ALDH1A1 | |
| SCHEMBL3753897 | 0.83 | NPC1 (0.53) | TSHRSMN1; SMN2MEN1NPC1ALDH1A1 | |
| SCHEMBL3740530 | 0.83 | NPC1 (0.56) | TSHRSMN1; SMN2MEN1NPC1ALDH1A1 | |
| SCHEMBL3741094 | 0.82 | NPC1 (0.52) | TSHRSMN1; SMN2MEN1NPC1ALDH1A1 | |
| SCHEMBL3746193 | 0.82 | NPC1 (0.52) | TSHRSMN1; SMN2MEN1NPC1ALDH1A1 | |
| SCHEMBL3742038 | 0.82 | NPC1 (0.52) | TSHRSMN1; SMN2MEN1NPC1ALDH1A1 | |
| SCHEMBL3749554 | 0.82 | NPC1 (0.52) | TSHRSMN1; SMN2MEN1NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7834039-B2 | Oxadiazole compounds | ABBOTT LABORATORIES (US) | 2010-11-16 | — | — | US | claimed |
| US-7834039-B2 | Oxadiazole compounds | ABBOTT LABORATORIES (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834039-B2 | Oxadiazole compounds | ABBOTT LABORATORIES (US) | 2010-11-16 | — | — | US | disclosed |
| US-7834039-B2 | Oxadiazole compounds | ABBOTT LABORATORIES (US) | 2010-11-16 | — | — | US | disclosed |
| EP-2109364-A1 | NOVEL OXADIAZOLE COMPOUNDS | Abbott Laboratories (US) | 2009-10-21 | — | — | EP | disclosed |
| US-20080280876-A1 | Novel oxadiazole compounds | ABBVIE INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080280876-A1 | Novel oxadiazole compounds | ABBVIE INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080280876-A1 | Novel oxadiazole compounds | ABBVIE INC. | 2008-11-13 | — | — | US | disclosed |
| WO-2008076356-A1 | NOVEL OXADIAZOLE COMPOUNDS | ABBOTT LABORATORIES (US) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280876-A1 | Novel oxadiazole compounds | S1PR3, S1PR1, S1PR2 | TSHR 1235/4885SMN1; SMN2 3564/4885MEN1 2929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.